// startup autopsy
Veritas Genetics
The startup that offered a $999 whole genome sequence could not find enough people who wanted one.
marketfitBankruptcy
Fatal mistake: No Product Market Fit
| Founded | 2014 |
|---|---|
| Closed | 2020 |
| Country | USA |
| Sector | Healthtech |
// the model, blind
Evaluating only Veritas Genetics’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: No market fit.
Key Events Timeline
FOUNDING
Veritas Genetics founded by George Church and colleagues to democratize whole genome sequencing.
PRODUCT LAUNCH
Veritas launches myGenome service offering whole genome sequencing for $999, breaking the $1,000 cost barrier.
FUNDING
Veritas Genetics secures Series B funding from BGI Genomics and other investors to expand direct-to-consumer operations.
REGULATORY ACTION
FDA and international regulators restrict direct-to-consumer genetic testing, limiting Veritas' market access in multiple countries.
DOWN ROUND
Veritas faces investor scrutiny over BGI's Chinese ownership, creating geopolitical complications and reduced funding appetite.
PIVOT
COVID-19 pandemic disrupts clinical partnerships and stalls hospital-based genomic sequencing initiatives at Veritas.
SHUTDOWN
Veritas Genetics files for bankruptcy in December 2020 after customer demand fails to materialize and regulatory barriers persist.